RDX 7675

Drug Profile

RDX 7675

Alternative Names: RDX 022; RDX 227675; RDX 7675

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ardelyx
  • Class Cardiovascular therapies; Polymers; Polystyrenes
  • Mechanism of Action Binding agents; Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperkalaemia

Most Recent Events

  • 21 Nov 2017 Ardelyx terminates a phase III trial in Hyperkalaemia in USA because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial(PO)
  • 21 Nov 2017 Ardelyx terminates a phase II trial for Hyperkalaemia in USA because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial (PO) (NCT03018067)
  • 21 Nov 2017 Ardelyx terminates a phase IIb trial for Hyperkalaemia in USA because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top